The analysis of anemia severity among patients with non-hematological malignancies revealed that moderate anemia (Hb 8.0-10.9 g/dL) was the most prevalent, affecting 60.5% of cases (n=52), underscoring chronic inflammation or malnutrition often linked to cancer progression. Severe anemia (Hb <8.0 g/dL) followed, impacting 25.5% of patients (n=22), a critical finding that highlights the urgency for clinical interventions such as transfusions or iron therapy. This evidence concerns the gene GSTM1 and cancer.